close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvalent, Inc. - Class A Common Stock (NQ:NUVL)

97.71 +4.32 (+4.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvalent, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Nuvalent (NUVL) Q2 R&D Up 65%
Via The Motley Fool
Nuvalent Inc-A (NASDAQ:NUVL) Reports Q2 2025 Earnings Miss with Focus on Oncology Pipeline Progress
Nuvalent (NUVL) reported Q2 2025 EPS of -$1.31, slightly missing estimates, with no revenue as expected. Shares rose pre-market as investors focus on its oncology pipeline, including zidesamtinib's NDA... 
Via Chartmill
Topics Earnings
Nuvalent Touts 'Positive' Data From Zidesamtinib Trial For Pretreated Patients With Advanced Form Of Lung Cancer
Nuvalent releases pivotal ARROS-1 trial data and plans to begin a rolling NDA submission for zidesamtinib in July 2025. 
Via Benzinga
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
 
Via Benzinga
Why Nuvalent (NUVL) Shares Are Down 6% Today
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each. 
Via Benzinga
NUVL Stock Earnings: Nuvalent Misses EPS for Q2 2024
NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
Via News Direct
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in... 
Via Benzinga
NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024
NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Recap: Nuvalent Q4 Earnings
 
Via Benzinga
Recap: Nuvalent Q3 Earnings
 
Via Benzinga
Where Nuvalent Stands With Analysts
 
Via Benzinga
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test. 
Via Investor's Business Daily
Topics Death
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
 
Via Benzinga
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
 
Via Benzinga
3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally
Although short-squeeze stocks to buy present great risk, betting against the bears can also yield dramatically robust returns. 
Via InvestorPlace
Why Nuvalent Stock Was Soaring Wednesday
The company reported preliminary data on a non-small cell lung cancer therapy. 
Via The Motley Fool
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Why Nuvalent Stock Tanked on Tuesday
The dilution monster stalked the company following the announcement of a new capital-raising effort. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance... 
Via Benzinga
Why Nuvalent Stock Skyrocketed 35% This Week
Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold
Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients,... 
Via Benzinga
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today